$RFL - Pharma8k's

12 Dec 2025 SEC Filing 8-K $RFL

Rafael Holdings (RFL) Reports Q1 Loss of $9.8M as Phase 3 NPC Trial Continues

Rafael Holdings (RFL) filed an 8-K on Dec 11, 2025, reporting a Q1 net loss of $9.8M and positive DMC review for its Phase 3 NPC drug trial.